Two Sigma Advisers
AVTX icon

Two Sigma Advisers’s Avalo Therapeutics AVTX Stock Holding History

Two Sigma Advisers’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-49,400
Closed -$897K – 216
2025
Q4 		$897K Buy
+49,400
New +$834K ﹤0.01% 1535
2022
Q2 		– Sell
-73
Closed -$152K – 2653
2022
Q1 		$152K Sell
73
-92
-56% -$231K ﹤0.01% 2430
2021
Q4 		$806K Sell
165
-113
-41% -$678K ﹤0.01% 1672
2021
Q3 		$1.75M Sell
278
-146
-34% -$1.18M ﹤0.01% 1328
2021
Q2 		$4M Buy
424
+284
+203% +$2.38M 0.01% 962
2021
Q1 		$1.22M Buy
140
+10
+8% +$94.5K ﹤0.01% 1547
2020
Q4 		$986K Sell
130
-31
-19% -$215K ﹤0.01% 1574
2020
Q3 		$1.05M Buy
161
+137
+571% +$1.03M ﹤0.01% 1483
2020
Q2 		$179K Buy
+24
New +$174K ﹤0.01% 2274

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Two Sigma Advisers's AVTX Position: Q1 2026 in Review

Two Sigma Advisers sold out of Avalo Therapeutics (AVTX) in Q1 2026, closing a stake of 49,400 shares — an estimated $897K sold.

Two Sigma Advisers first reported a position in AVTX in Q2 2020 and held it in 9 quarters. The position peaked at $4M in Q2 2021. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Two Sigma Advisers reported no remaining Avalo Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 49,400 Avalo Therapeutics shares in Q1 2026, an estimated $897K.
  • Two Sigma Advisers first reported a position in Avalo Therapeutics in Q2 2020 and held it in 9 quarters.
  • Two Sigma Advisers's Avalo Therapeutics position peaked at $4M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.